Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
Tevogen Bio (Nasdaq: TVGN) met with BARDA's TechWatch team to discuss their ExacTcell™ technology as a potential medical countermeasure. The meeting focused on three key aspects: the company's affordable and scalable ExacTcell platform, positive results from the proof-of-concept clinical trial for TVGN 489, and the integration of Artificial Intelligence in their manufacturing processes.
The discussion highlighted ExacTcell's capability to rapidly adapt to emerging viral threats, positioning it as a potential solution for public health protection. The company plans to continue discussions with key federal entities and maintain stakeholder communication regarding developments with the VITAL Biotech Accelerator Program and the Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense.
Tevogen Bio (Nasdaq: TVGN) ha incontrato il team TechWatch di BARDA per discutere della loro tecnologia ExacTcell™ come potenziale contromisura medica. L'incontro si è concentrato su tre aspetti chiave: la piattaforma ExacTcell economica e scalabile dell'azienda, i risultati positivi dallo studio clinico di prova di concetto per TVGN 489 e l'integrazione dell'Intelligenza Artificiale nei loro processi di produzione.
La discussione ha messo in evidenza la capacità di ExacTcell di adattarsi rapidamente alle emergenti minacce virali, posizionandola come una potenziale soluzione per la protezione della salute pubblica. L'azienda prevede di continuare i colloqui con importanti enti federali e mantenere la comunicazione con le parti interessate riguardo ai progressi nel Programma di Accelerazione Biotech VITAL e nell'Ufficio Esecutivo del Programma Congiunto del Dipartimento della Difesa per la Difesa Chimica, Biologica, Radiologica e Nucleare.
Tevogen Bio (Nasdaq: TVGN) se reunió con el equipo TechWatch de BARDA para discutir su tecnología ExacTcell™ como una potencial contramedida médica. La reunión se centró en tres aspectos clave: la plataforma ExacTcell de la empresa, asequible y escalable, los resultados positivos del ensayo clínico de prueba de concepto para TVGN 489 y la integración de la Inteligencia Artificial en sus procesos de fabricación.
La discusión destacó la capacidad de ExacTcell para adaptarse rápidamente a las amenazas virales emergentes, posicionándola como una posible solución para la protección de la salud pública. La empresa planea continuar las discusiones con entidades federales clave y mantener la comunicación con las partes interesadas sobre los avances en el Programa de Aceleración Biotech VITAL y la Oficina Ejecutiva del Programa Conjunto del Departamento de Defensa para la Defensa Química, Biológica, Radiológica y Nuclear.
Tevogen Bio (Nasdaq: TVGN)은 BARDA의 TechWatch 팀과 만나 그들의 ExacTcell™ 기술을 잠재적인 의학적 반응책으로 논의했습니다. 회의는 회사의 저렴하고 확장 가능한 ExacTcell 플랫폼, TVGN 489에 대한 개념 증명 임상 시험의 긍정적인 결과, 제조 과정에 인공지능 통합이라는 세 가지 주요 측면에 초점을 맞췄습니다.
논의는 ExacTcell이 새롭게 등장하는 바이러스 위협에 빠르게 적응할 수 있는 능력을 강조하며 이를 공공 건강 보호를 위한 잠재적 솔루션으로 자리매김했습니다. 이 회사는 주요 연방 기관과의 논의를 계속하고 VITAL 생명 과학 가속기 프로그램 및 국방부의 화학, 생물, 방사능 및 핵 방어를 위한 합동 프로그램 집행 사무소의 발전에 대해 이해관계자와의 소통을 유지할 계획을 가지고 있습니다.
Tevogen Bio (Nasdaq: TVGN) a rencontré l'équipe TechWatch de BARDA pour discuter de leur technologie ExacTcell™ en tant que contre-mesure médicale potentielle. La réunion a porté sur trois aspects clés : la plateforme ExacTcell de l'entreprise, abordable et évolutive, les résultats positifs de l'essai clinique de preuve de concept pour TVGN 489 et l'intégration de l'intelligence artificielle dans leurs processus de fabrication.
La discussion a souligné la capacité d'ExacTcell à s'adapter rapidement aux menaces virales émergentes, la positionnant comme une solution potentielle pour la protection de la santé publique. L'entreprise envisage de poursuivre les discussions avec des entités fédérales clés et de maintenir la communication avec les parties prenantes concernant les développements du programme VITAL Biotech Accelerator et le Bureau Exécutif du Programme Commun du Département de la Défense pour la défense chimique, biologique, radiologique et nucléaire.
Tevogen Bio (Nasdaq: TVGN) traf sich mit dem TechWatch-Team von BARDA, um über ihre ExacTcell™-Technologie als potenzielle medizinische Gegenmaßnahme zu diskutieren. Das Treffen konzentrierte sich auf drei zentrale Aspekte: die erschwingliche und skalierbare ExacTcell-Plattform des Unternehmens, positive Ergebnisse aus der Proof-of-Concept-Studie für TVGN 489 und die Integration von Künstlicher Intelligenz in die Produktionsprozesse.
Die Diskussion hob die Fähigkeit von ExacTcell hervor, sich schnell an neu auftretende Virusbedrohungen anzupassen, wodurch es als potenzielle Lösung zum Schutz der öffentlichen Gesundheit positioniert wird. Das Unternehmen plant, die Gespräche mit wichtigen Bundesbehörden fortzusetzen und die Kommunikation mit den Stakeholdern in Bezug auf Entwicklungen im VITAL Biotech Accelerator-Programm und das Joint Program Executive Office des Verteidigungsministeriums für chemische, biologische, radiologische und nukleare Verteidigung aufrechtzuerhalten.
- Successful meeting with BARDA TechWatch team, indicating potential government interest
- Positive results reported from TVGN 489 proof-of-concept clinical trial
- Technology demonstrates rapid adaptation capabilities for viral threats
- None.
WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio’s affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its process and future manufacturing capabilities.
During the meeting, Tevogen Bio discussed ExacTcell’s unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health. Tevogen Bio will follow up with key federal entities and continue to update stakeholders.
- VITAL Biotech Accelerator Program
- Department of Defense - Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense
- Antivirals and Antitoxins Branch within BARDA’s Division of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d566f0b7-923e-490e-b13f-50284c886cd7
FAQ
What were the key points discussed in Tevogen Bio's meeting with BARDA TechWatch?
What is the significance of ExacTcell technology for public health?
What are the next steps for Tevogen Bio (TVGN) following the BARDA meeting?
What government agencies are involved with Tevogen Bio's ExacTcell development?
